Terms: = Endocrine gland cancer AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src
558 results:
1. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract] [Full Text] [Related]
2. The emerging roles of CEACAM6 in human cancer (Review).
Wu G; Wang D; Xiong F; Wang Q; Liu W; Chen J; Chen Y
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240103
[TBL] [Abstract] [Full Text] [Related]
3. Compartment-specific multiomic profiling identifies src and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract] [Full Text] [Related]
4. MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
[TBL] [Abstract] [Full Text] [Related]
5. Radiation-Activated Cobalamin-Kinase Inhibitors for Treatment of Pancreatic Ductal Adenocarcinoma.
Gendron LN; Sheveland CG; Gunn JR; Pogue BW; Shell TA; Shell JR
Mol Pharm; 2024 Jan; 21(1):137-142. PubMed ID: 37989273
[TBL] [Abstract] [Full Text] [Related]
6. Direct regulation of FNIP1 and FNIP2 by MEF2 sustains MTORC1 activation and tumor progression in pancreatic cancer.
Xia L; Nie T; Lu F; Huang L; Shi X; Ren D; Lu J; Li X; Xu T; Cui B; Wang Q; Gao G; Yang Q
Autophagy; 2024 Mar; 20(3):505-524. PubMed ID: 37772772
[TBL] [Abstract] [Full Text] [Related]
7. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
8. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual src and MEK1/2 inhibition.
Rose MM; Nassar KW; Sharma V; Schweppe RE
Med Oncol; 2023 Sep; 40(10):299. PubMed ID: 37713162
[TBL] [Abstract] [Full Text] [Related]
9. src is a target molecule of mannose against pancreatic cancer cells growth in vitro & in vivo.
Xie J; Wu S; Liao W; Ning J; Ding K
Glycobiology; 2023 Oct; 33(10):766-783. PubMed ID: 37658770
[TBL] [Abstract] [Full Text] [Related]
10. Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS.
Chao A; Huang HJ; Lin CY; Lee CH; Lin CH; Chao AS; Lai CH; Chang TC; Wu KY; Wu RC
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37655726
[TBL] [Abstract] [Full Text] [Related]
11. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated src/PI3K/Akt signaling pathway.
Xu R; Song J; Ruze R; Chen Y; Yin X; Wang C; Zhao Y
Cell Death Dis; 2023 Aug; 14(8):497. PubMed ID: 37542052
[TBL] [Abstract] [Full Text] [Related]
12. Starvation-inactivated MTOR triggers cell migration via a ULK1-SH3PXD2A/TKS5-MMP14 pathway in ovarian carcinoma.
Lin CY; Wu KY; Chi LM; Tang YH; Huang HJ; Lai CH; Tsai CN; Tsai CL
Autophagy; 2023 Dec; 19(12):3151-3168. PubMed ID: 37505094
[TBL] [Abstract] [Full Text] [Related]
13. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity.
Bolf EL; Beadnell TC; Rose MM; D'Alessandro A; Nemkov T; Hansen KC; Schweppe RE
Cells; 2023 May; 12(10):. PubMed ID: 37408209
[TBL] [Abstract] [Full Text] [Related]
14. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract] [Full Text] [Related]
15. Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre.
Gutic B; Bozanovic T; Mandic A; Dugalic S; Todorovic J; Dugalic MG; Sengul D; Detanac DA; Sengul I; Detanac D; Kesicioglu T; Soares Junior JM
Clinics (Sao Paulo); 2023; 78():100204. PubMed ID: 37148829
[TBL] [Abstract] [Full Text] [Related]
16. Functional roles of src signaling in pancreatic cancer: Recent insights provide novel therapeutic opportunities.
Poh AR; Ernst M
Oncogene; 2023 Jun; 42(22):1786-1801. PubMed ID: 37120696
[TBL] [Abstract] [Full Text] [Related]
17. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract] [Full Text] [Related]
18. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment.
Yin Z; Chen S
Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
[TBL] [Abstract] [Full Text] [Related]
19. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
Jiang Y; Song L; Lin Y; Nowialis P; Gao Q; Li T; Li B; Mao X; Song Q; Xing C; Zheng G; Huang S; Jin L
Oncogene; 2023 May; 42(20):1672-1684. PubMed ID: 37020040
[TBL] [Abstract] [Full Text] [Related]
20. Network pharmacology-based anti-pancreatic cancer potential of kaempferol and catechin of Trema orientalis L. through computational approach.
Agrawal S; Das R; Singh AK; Kumar P; Shukla PK; Bhattacharya I; Tripathi AK; Mishra SK; Tiwari KN
Med Oncol; 2023 Apr; 40(5):133. PubMed ID: 37010624
[TBL] [Abstract] [Full Text] [Related]
[Next]
